Artimplant and Small Bone Innovations, Inc. revise terms of five License, Supply and Distribution agreements

Artimplant and Small Bone Innovations, Inc. revise terms of five License, Supply
and Distribution agreements 

Västra Frölunda, Sweden, February 2nd , 2009
Artimplant and Small Bone Innovations, Inc. (SBi) have agreed to amend and
consolidate the terms of five different License, Supply and Distribution
agreements relating to the Artelon® range of biodegradable spacers. The
agreements have been converted to non-exclusive in exchange for lower minimum
sales commitments from SBi. Artimplant has committed to support SBi with
additional clinical documentation in exchange for a higher share of profit from
SBi sales.  The revisions are retroactive to January 1, 2009.

Conference call, in Swedish, regarding the changed agreements at 11 am (GMT+1),
today February 2, 2009. Dial-in details will be available at
http://www.artimplant.com/investors-media/presentations.html before the call.

Artimplant and SBi are parties to five license, supply and distribution
agreements covering the Artelon® CMC Spacer, CMC Spacer Arthro, MTP Spacer, STT
Spacer and DRU Spacer (“Original Agreements”). Artimplant and SBi have
renegotiated the following material terms of the Original Agreements that have
been incorporated into a single new restated agreement (“New Agreement”):

- The Agreements have been converted to non-exclusive.
- Minimum sales quotas are lowered and SBi's geographical territory is adjusted.
- Artimplant commits to support SBi with additional clinical documentation.
- The payment due to Artimplant per unit sale is significantly increased.
- The Initial Term of the New Agreement will run from 1/1/09 - 12/31/14.
- An option agreement providing Artimplant the right to sell and SBi the right
to purchase regulatory files have been terminated. 

Long-term the changes in terms are deemed to be very positive for both SBi and
Artimplant. Artimplant will take on an increased responsibility in strengthening
the clinical documentation and SBi will receive a stronger scientific basis on
which it can increase sales. Moreover, the New Agreement enables Artimplant to
more actively work in collaboration with SBi's management to drive sales in and
outside the U.S.

In the short-term, the changes are cash-flow negative for Artimplant. The
changes release SBi from its bi-annual purchase and sales obligations under the
Original Agreements, as well as releasing the company from its obligation to
purchase regulatory files from Artimplant. However, the increased flexibility
and anticipated growth of Artelon® Spacer products with higher returns make the
changes very attractive for both companies.

Hans Rosén, CEO of Artimplant says;
“We are very pleased to improve both margin and flexibility in our business
relationship with SBi. The revised agreement will create a more efficient
working relationship where the respective strength of the partners is better
utilized. SBi is our primary business partner for resurfacing of small bones and
joints. Artimplant will increase its efforts to support the growth of SBi sales
in a long term prosperous relationship.”

Anthony G. Viscogliosi, Chairman and CEO of SBI says;
“We are delighted to have revised our working agreements to create greater
synergies between SBi's marketing and distribution strength and Artimplant's
research, development, clinical documentation and manufacturing skills.  The New
Agreement provides increased incentive for both our companies to continue to
build the Artelon® brand. To date, the Artelon® platform has been an important
part of SBi's success, and this New Agreement promises to strengthen Artelon's
role as a key element of our upper limb portfolio.”

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral surgery and veterinary
medical applications. 

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Small Bone Innovations
Small Bone Innovations, Inc. (SBi) is a private company and was founded in 2004
by Viscogliosi Brothers, LLC, (VB), the New York-based merchant banking firm
that specializes in the musculoskeletal/orthopedic sector. VB created SBi as the
first company to focus purely on small bone & joint science. By integrating
established companies and professionals in the field, SBi offers a broad,
clinically proven portfolio of products and technologies to treat trauma and
diseases in small bones & joints. Today, SBi has more than 130 employees at
facilities in New York, NY, Morrisville, PA, and Bourg-en-Bresse, France. 

For more information on SBi, please visit: www.totalsmallbone.com 

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish
Financial Instruments Act and the Swedish Securities Exchange and Clearing
Operations Act and/or stock market agreements. Information was made available
for publication on February 2, 2009 at 8:45 am (GMT+1).